Teclistamab BCMA × CD3 bispecific (with step-up dosing) — continuous SC weekly
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-TECLISTAMAB |
|---|
| ID | REG-TECLISTAMAB |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MM-2025 |
Notes
MajesTEC-1 (Moreau 2022, ASH 2023 update): triple-class refractory MM after ≥3 prior lines (median 5 prior) — ORR 63%, CR/sCR 39%, mPFS ~11 mo, mDOR ~22 mo. Approved 4L+ triple-class refractory (post-PI, post-IMiD, post-anti-CD38). Step-up dosing inpatient REQUIRED. Talquetamab (GPRC5D × CD3, MonumenTAL-1) and elranatamab (BCMA × CD3, MagnetisMM-3) are alternative bispecifics — separate future Regimen entities. CAR-T (cilta-cel, ide-cel) is the alternative cellular approach if accessible.
Used By
Indication
IND-MM-4L-TECLISTAMAB- IND-MM-4L-TECLISTAMABIND-MM-RR-3L-TECLISTAMAB- IND-MM-RR-3L-TECLISTAMAB